Tech Company Financing Transactions
Recursion Pharmaceuticals Funding Round
On 10/4/2017, Recursion Pharmaceuticals landed $60 million in Series B funding from Data Collective, Advantage Capital Partners and AME Cloud Ventures.
Transaction Overview
Company Name
Announced On
10/4/2017
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
41S Rio Grande St.
Salt Lake City, UT 84101
USA
Salt Lake City, UT 84101
USA
Phone
Website
Email Address
Overview
At Recursion, we are Making Rare Diseases History. We combine innovative biological science with advanced computational algorithms to discover new therapeutic opportunities for rare genetic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Gibson
Chief Financial Officer
Michael Secora
Chief Operating Officer
Tina Larson
Chief Scientific Officer
Sharath Hegde
Chief Technical Officer
Benjamin Mabey
Vice President
Ron Alfa
Vice President
Kevin Brown
Vice President
Yolanda Chong
Vice President
Michael Genin
Vice President
Imran Haque
Vice President
Kristen Rushton
VP - Bus. Development
Matthew Kinn
VP - Bus. Development
Shaf Virani
VP - Finance
Nathan Hatfield
VP - Finance
Kevin Leggat
VP - Human Resources
Brooke Clark
VP - Operations
Adeline Low
VP - Product Management
Heather Kirkby
VP - Product Management
Lina Nilsson
VP - Product Management
Mason Victors
Browse more venture capital transactions:
Prev: 10/4/2017: Frame.io venture capital transaction
Next: 10/4/2017: myStrength venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs